Astellas Taps Proteostasis In Potential $1.2bn Alliance
This article was originally published in PharmAsia News
Executive Summary
Assuming all milestones are met and options exercised, a new deal with Japan's Astellas will provide a bonanza for Proteostasis, being worth potentially more than $1.2 billion to the privately held U.S. drug discovery venture.
You may also be interested in...
VC Roundup: Cleave Raises $37m To Maintain Phase I Momentum, Plus $233.5m In Recent Financings
Cleave Biosciences leads off a recent slate of venture capital financings with $37m to fund ongoing Phase I programs for the lead drug from its protein homeostasis-focused platform.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.